Prepared By R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C., 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date Of Report (Date Of Earliest Event Reported):  05/02/2005
 
Tercica, Inc.
(Exact Name of Registrant as Specified in its Charter)
 
Commission File Number:  000-50461
 
Delaware
  
26-0042539
(State or Other Jurisdiction of
  
(I.R.S. Employer
Incorporation or Organization)
  
Identification No.)
 
651 Gateway Boulevard
Suite 950
South San Francisco, CA 94080
(Address of Principal Executive Offices, Including Zip Code)
 
(650) 624-4900
(Registrant’s Telephone Number, Including Area Code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
 

Items to be Included in this Report

 
Item 8.01.    Other Events
 
On May 2, 2005, Terica, Inc. (the "Company") issued a press release to announce that the Company has received Priority Review notification from the U.S. Food and Drug Administration for the New Drug Application for its drug candidate IncrelexTM (mecasermin [rDNA origin] injection). The Company's press release is attached as Exhibit 99.1 to this report on Form 8-K and incorporated herein by reference.
 
 
Item 9.01.    Financial Statements and Exhibits
 
Press Release issued by Tercica, Inc. on May 2, 2005.
 

 

Signature(s)
 
Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.
 
      
 
Tercica, Inc.
 
 
Date: May 02, 2005.
     
By:
 
/s/    Stephen N. Rosenfield
               
Stephen N. Rosenfield
               
Senior Vice President of Legal Affairs
 
 

 

Exhibit Index
 
Exhibit No.
  
Description
EX-99.1
  
Press Release entitled "FDA Accepts Tercica's IncrelexTM New Drug Application With Priority Review for the Treatment of Short Stature," dated May 2, 2005